Erratum: Suramin: A potential therapy for diabetic nephropathy (PLoS ONE (2013) 8:9 (e73655) DOI: 10.1371/journal.pone.0073655);Suramin: A Potential Therapy for Diabetic Nephropathy

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Korrapati, Midhun C ^a   Howell, Lauren H ^a   Shaner, Brooke E ^a   Megyesi, Judit K ^b   Siskind, Leah J ^a,c   Schnellmann, Rick G ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGEN 1A2; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; SMAD3 PROTEIN; SURAMIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; URINARY EXCRETION; URINE VOLUME;

ANIMALIA; MUS;

ACTINS; ANIMALS; COLLAGEN TYPE I; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH; NF-KAPPA B; RECEPTORS, LEPTIN; SMAD3 PROTEIN; SURAMIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TRYPANOCIDAL AGENTS;

EID: 84883621067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114426     Document Type: Erratum

References (48)

1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, et al. (2004) Nephropathy in diabetes. Diabetes care 27Suppl 1: S79-83.
2. Reutens AT, Atkins RC, (2011) Epidemiology of diabetic nephropathy. Contributions to nephrology 170: 1-7.
3. Ruggenenti P, Cravedi P, Remuzzi G, (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature reviews. Nephrology 6: 319-330.
4. Kopple JD, Feroze U, (2011) The effect of obesity on chronic kidney disease. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation 21: 66-71.
5. Mathew A, Cunard R, Sharma K, (2011) Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol 170: 217-227.
6. Najafian B, Alpers CE, Fogo AB, (2011) Pathology of human diabetic nephropathy. Contrib Nephrol 170: 36-47.
7. Kanwar YS, Sun L, Xie P, Liu FY, Chen S, (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual review of pathology 6: 395-423.
8. Sharma K, McCue P, Dunn SR, (2003) Diabetic kidney disease in the db/db mouse. American journal of physiology. Renal physiology 284: F1138-1144.
9. Tesch GH, Lim AK, (2011) Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. American journal of physiology. Renal physiology 300: F301-310.
10. Peters V, Schmitt CP, (2012) Murine models of diabetic nephropathy. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology and German Diabetes Association 120: 191-193.
11. Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M, (2009) Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions Pharmacological research: the official journal of the Italian Pharmacological Society. 60: 24-32.
12. Sharma B, Balomajumder C, Roy P, (2008) Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 46: 2376-2383.
13. Liu N, Zhuang S, (2011) Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug. Current clinical pharmacology 6: 137-142.
14. Zhuang S, Lu B, Daubert RA, Chavin KD, Wang L, et al. (2009) Suramin promotes recovery from renal ischemia/reperfusion injury in mice. Kidney international 75: 304-311.
15. Korrapati MC, Shaner BE, Schnellmann RG, (2012) Recovery from glycerol-induced acute kidney injury is accelerated by suramin. The Journal of pharmacology and experimental therapeutics 341: 126-136.
16. Kuhad A, Chopra K, (2009) Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life sciences 84: 296-301.
17. Soldatos G, Cooper ME, (2008) Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes research and clinical practice 82Suppl 1: S75-79.
18. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, et al. (2007) Oxidative stress and cellular stress response in diabetic nephropathy. Cell stress & chaperones 12: 299-306.
19. Korrapati MC, Shaner BE, Neely BA, Alge JL, Arthur JM, et al. (2012) Diabetes-induced renal injury in rats is attenuated by suramin. The Journal of pharmacology and experimental therapeutics 343: 34-43.
20. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, et al. (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutrition & metabolism 8: 35.
21. Tang SC, Leung JC, Lai KN, (2011) Diabetic tubulopathy: an emerging entity. Contributions to nephrology 170: 124-134.
22. Fornoni A, Ijaz A, Tejada T, Lenz O, (2008) Role of inflammation in diabetic nephropathy. Current diabetes reviews 4: 10-17.
23. Rahimi RA, Leof EB, (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102: 593-608.
24. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. The New England journal of medicine 361: 40-51.
25. Titan SM, M. Vieira J J, Dominguez WV, Barros RT, Zatz R, (2011) ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. Clinical nephrology 76: 273-283.
26. Collins JM, Klecker RW Jr, Yarchoan R, Lane HC, Fauci AS, et al. (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. Journal of clinical pharmacology 26: 22-26.
27. Remuzzi G, Schieppati A, Ruggenenti P, (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. The New England journal of medicine 346: 1145-1151.
28. Iseki K, Ikemiya Y, Iseki C, Takishita S, (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney international 63: 1468-1474.
29. Iseki K, Kinjo K, Iseki C, Takishita S, (2004) Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. American journal of kidney diseases: the official journal of the National Kidney Foundation 44: 806-814.
30. Cohen MP, Lautenslager GT, Shearman CW, (2001) Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism: clinical and experimental 50: 1435-1440.
31. Gartner K, (1978) Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). Diabetologia 15: 59-63.
32. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, et al. (2007) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. American journal of physiology. Renal physiology 292: F1141-1150.
33. Nayak BK, (2005) Changing times, evolving responses. Indian journal of ophthalmology 53: 1-3.
34. Wu CC, Sytwu HK, Lu KC, Lin YF, (2011) Role of T cells in type 2 diabetic nephropathy. Experimental diabetes research 2011: 514738.
35. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, et al. (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. Journal of the American Society of Nephrology: JASN 23: 86-102.
36. Eltzschig HK, Sitkovsky MV, Robson SC, (2012) Purinergic signaling during inflammation. The New England journal of medicine 367: 2322-2333.
37. Genetos DC, Karin NJ, Geist DJ, Donahue HJ, Duncan RL, (2011) Purinergic signaling is required for fluid shear stress-induced NF-kappaB translocation in osteoblasts. Exp Cell Res 317: 737-744.
38. Goto T, Takeuchi S, Miura K, Ohshima S, Mikami K, et al. (2006) Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-kappaB activity. Cytokine 33: 28-35.
39. Song JH, Cha SH, Lee HJ, Lee SW, Park GH, et al. (2006) Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 21: 683-689.
40. Wang LH, Liu JS, Ning WB, Yuan QJ, Zhang FF, et al. (2011) Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. Pharmacology 88: 88-99.
41. Liu N, Tolbert E, Ponnusamy M, Yan H, Zhuang S, (2011) Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. The Journal of pharmacology and experimental therapeutics 338: 758-766.
42. Xiao H, Shen HY, Liu W, Xiong RP, Li P, et al. (2013) Adenosine A2A receptor: a target for regulating renal interstitial fibrosis in obstructive nephropathy. PLoS One 8: e60173.
43. Quezada C, Alarcon S, Jaramillo C, Munoz D, Oyarzun C, et al. (2013) Targeting adenosine signaling to treatment of diabetic nephropathy. Curr Drug Targets 14: 490-496.
44. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. The Journal of pathology 214: 199-210.
45. Fragiadaki M, Witherden AS, Kaneko T, Sonnylal S, Pusey CD, et al. (2011) Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biol 30: 396-403.
46. Rastaldi MP, Ferrario F, Giardino L, Dell'Antonio G, Grillo C, et al. (2002) Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62: 137-146.
47. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, et al. (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97.
48. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, et al. (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350.